Marc Voigt
Fortune : 240 715 $ au 31/10/2026
Fortune : 240 715 $ au 31/10/2026
Mr. Marc Voigt is a Chairman-Supervisory Board & President at Immutep SAS, a Chief Executive Officer & Executive Director at Immutep Ltd., a Co-Managing Director at Immutep GmbH and a Member at Pharma-Lizenz-Club Deutschland.
He is on the Board of Directors at Immutep Ltd. Mr. Voigt was previously employed as a Vice Chairman-Supervisory Board by Elanix Biotechnologies AG, a MD, Chief Operating & Financial Officer by caprotec bioanalytics GmbH, a Chief Financial Officer by Revotar Biopharmaceuticals AG, a Director-Executive Board by Allianz SE, a Principal by Allianz Versicherungs AG, a Director-Finance, Legal & Business Development by Medical Enzymes AG, and a General Manager-European Operations by Immutep GmbH.
He received his MBA from Freie Universität Berlin.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMUTEP LTD 1,01% | 09/10/2026 | 14 877 345 ( 1,01% ) | 240 715 $ | 31/10/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| IMMUTEP LIMITED | Directeur Général | 09/07/2014 |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Directeur Général | - |
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Develops T-cell response-based immuno therapeutics for the treatment of cancer and infectious diseases | Président | 18/11/2015 |
Pharma-Lizenz-Club Deutschland | Corporate Officer/Principal | - |
| Sociétés | Poste | Fin |
|---|---|---|
Medical Enzymes AG
Medical Enzymes AG Medical/Nursing ServicesHealth Services Develops product family based on amino acid depleting enzymes | Directeur Financier/CFO | 02/01/2006 |
Revotar Biopharmaceuticals AG
Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Develops anti-inflammatory drugs | Directeur Financier/CFO | 02/01/2006 |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Corporate Officer/Principal | - |
Allianz Versicherungs AG
Allianz Versicherungs AG Multi-Line InsuranceFinance Provides motor, property, liability and accident insurance services | Corporate Officer/Principal | - |
| ALLIANZ SE | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 11 |
|---|---|
Allianz SE
Allianz SE Multi-Line InsuranceFinance Provides property, casualty, life and health insurance & asset management services | Finance |
Immutep Ltd.
Immutep Ltd. BiotechnologyHealth Technology Engages in the development of anti-cancer therapeutics | Health Technology |
Elanix Biotechnologies AG
Elanix Biotechnologies AG BiotechnologyHealth Technology Develops and commercializes products for acute wound care, dermatological, and gynecological applications | Health Technology |
Revotar Biopharmaceuticals AG
Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Develops anti-inflammatory drugs | Health Technology |
Allianz Versicherungs AG
Allianz Versicherungs AG Multi-Line InsuranceFinance Provides motor, property, liability and accident insurance services | Finance |
Freie Universität Berlin
Freie Universität Berlin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
caprotec bioanalytics GmbH
caprotec bioanalytics GmbH BiotechnologyHealth Technology Commercializes Capture Compound Mass Spectrometry technology | Health Technology |
Medical Enzymes AG
Medical Enzymes AG Medical/Nursing ServicesHealth Services Develops product family based on amino acid depleting enzymes | Health Services |
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Develops T-cell response-based immuno therapeutics for the treatment of cancer and infectious diseases | Health Technology |
Pharma-Lizenz-Club Deutschland | |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national